CRABP2 has been found to be overexpressed in multiple cancers including bladder cancer48, Wilms tumor49, neuroblastoma50, pancreatic ductal adenocarcinoma51, serous sarcoma52, and non-small cell lung cancer (NSCLC)5–7. Here, CRABP2 is linked to non-small cell lung carcinoma.